G
GRI Bio, Inc. (GRI)
NCM – Real vaqt narxi. Valyuta: USD
2.28
+0.02 (0.88%)
Yopilishda: May 12, 2026, 4:00 PM EDT
2.29
+0.01 (0.50%)
Bozordan keyin: May 12, 2026, 5:09 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.28
+0.02 (0.88%)
Yopilishda: May 12, 2026, 4:00 PM EDT
2.29
+0.01 (0.50%)
Bozordan keyin: May 12, 2026, 5:09 PM EDT
GRI Bio, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Amerika Qo'shma Shtatlarida yallig'lanish, fibrotik va otoimmün kasalliklarga olib keladigan kasalliklarni davolash usullarini kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning asosiy mahsulot nomzodi GRI-0621, 1-toifa tabiiy killer T hujayralarining og'iz orqali qabul qilinadigan ingibitori bo'lib, u idiopatik o'pka fibozi kabi og'ir fibrotik o'pka kasalliklarini davolash uchun IIa fazali klinik sinovdan o'tmoqda. Kompaniyaning portfelida, shuningdek, otoimmün kasalliklarni davolash uchun preklinik rivojlanishda bo'lgan 2-toifa tabiiy killer T hujayralarining yangi og'iz orqali qabul qilinadigan agonisti GRI-0803; 500 dan ortiq birikmalardan iborat xususiy kutubxona; hamda yallig'lanishli immunitet reaktsiyalarini muvozanatlash uchun GRI-0124 va GRI-0729 mavjud. Kompaniya ilgari Glycoregimmune, Inc. nomi bilan tanilgan. GRI Bio, Inc. 2009 yilda tashkil etilgan va Kaliforniyaning La Jolla shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Albert Agro Ph.D. | Co-Founder & Chief Medical Officer |
| Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. W. Marc Hertz Ph.D. | Co-Founder, CEO, President & Director |
| Ms. Leanne M. Kelly | CFO & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-02-04 | 8-K | val-20260204.htm |
| 2026-01-30 | CORRESP | filename1.htm |
| 2026-01-28 | 8-K | val-20260128.htm |
| 2026-01-21 | 8-K | val-20260121.htm |
| 2026-01-16 | 8-K | val-20260115.htm |
| 2026-01-15 | 8-K | val-20260115.htm |
| 2026-01-08 | 8-K | val-20260108.htm |
| 2025-12-29 | DEF 14A | gridefinitiveproxystatemen.htm |
| 2025-12-19 | PRE 14A | gripreliminaryproxystateme.htm |
| 2025-12-12 | 8-K | val-20251212.htm |